Drugs / IGSC-C
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02604810 | Jan 2016 → Sep 2017 | immunodeficiency disease | Grifols Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGSC-C | “This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune globulin subcutaneous, human - klhw 20% solution (IGSC-C 20%) in...” PMID 31621458 ↗ Oct 2019 |
| Known as | immune globulin subcutaneous, human - klhw | “This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune globulin subcutaneous, human - klhw 20% solution (IGSC-C 20%) in...” PMID 31621458 ↗ Oct 2019 |
| Modality | Protein / enzyme biologic | “immune globulin subcutaneous, human - klhw 20% solution” PMID 31621458 ↗ Oct 2019 |
| Route | Subcutaneous | “SC administration of IGSC 20%” NCT02604810 ↗ |